Description
NCLT approved merger of Ind-Swift Limited into Ind-Swift Laboratories Limited with 15:100 share exchange ratio, effective August 14, 2025.
Summary
BSE has announced the amalgamation of Ind-Swift Limited (524652) into Ind-Swift Laboratories Limited as approved by NCLT Chandigarh Bench. Trading in Ind-Swift Limited shares will be suspended from August 14, 2025, with shareholders receiving 15 equity shares of Ind-Swift Laboratories Limited for every 100 shares held.
Key Points
- NCLT Chandigarh Bench approved Scheme of Arrangement for amalgamation
- Ind-Swift Limited (Transferor Company) merging into Ind-Swift Laboratories Limited (Transferee Company)
- Share exchange ratio: 15 equity shares of Rs. 10/- face value for every 100 equity shares of Rs. 2/- face value
- Complete trading suspension from August 14, 2025
- Record date fixed as August 14, 2025
Regulatory Changes
Implementation of NCLT approved Scheme of Arrangement resulting in complete merger of two entities with mandatory share conversion for all existing shareholders.
Compliance Requirements
- Trading members must not deal in Ind-Swift Limited equity shares from August 14, 2025
- Shareholders automatically entitled to new shares in Ind-Swift Laboratories Limited based on holdings as of record date
- No action required from shareholders as conversion is automatic
Important Dates
- Record Date: August 14, 2025
- Trading Suspension Date: August 14, 2025
- Notice Date: August 11, 2025
Impact Assessment
High impact corporate action requiring complete cessation of trading in the transferor company. All existing shareholders will receive shares in the transferee company at predetermined ratio, fundamentally changing their investment structure. Trading suspension ensures orderly transition during amalgamation process.
Impact Justification
Complete trading suspension and mandatory corporate action affecting all shareholders